Skip to content

People with HIV still running out of treatment options – not always because of resistance

Mareike Günsche | www.aspect-us.com

Top 5 HIV treatment stories from CROI 2022

Professor Samir Gupta (top right) presenting a study on lenacapavir at CROI 2022.

Lenacapavir shows continued promise for first-line treatment and highly resistant HIV

Professor Samir Gupta (top right) at CROI 2022.

New cases of multi-drug resistant HIV becoming rarer in Europe

Dr Barbara Rossetti presenting to EACS 2021.

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy

Peter Stanic/Pixabay

Heavily treatment-experienced people in Europe do not have a higher risk of clinical events

A variety of antiretroviral drugs used to treat HIV infection. Credit: NIAID. Creative Commons licence.

HIV capsid inhibitor offers new option for people with highly resistant HIV

Professor Sorana Segal-Maurer (right) presenting to CROI 2021.

Monoclonal antibody ibalizumab maintains HIV suppression for nearly a decade

Image by UNAMID. Creative Commons licence.

Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity

Image: Tero Vesalainen/Shutterstock.com